Alpha Tau Medical Ltd. announced its financial results for the first quarter of 2025, reporting an increase in R&D expenses to $7.2 million from $6.4 million in the same period in 2024. This rise was attributed to increased employee compensation and benefits, higher production expenses, and reduced government grants, although offset by lower share-based compensation expenses. Marketing expenses remained stable at $0.5 million, unchanged from the first quarter of 2024. Meanwhile, general and administrative expenses increased to $1.7 million from $1.4 million in the previous year, primarily due to unspecified factors. The company also highlighted significant corporate developments, including the completion of a $36.9 million registered direct financing and strategic marketing alliance with an affiliate of Oramed Pharmaceuticals, Inc. Furthermore, Alpha Tau received an Investigational Device Exemption $(IDE)$ from the FDA to conduct a U.S. pilot study of Alpha DaRT in patients with recurrent glioblastoma multiforme. Additionally, Alpha Tau shared promising interim results from trials of Alpha DaRT in treating pancreatic cancer and head and neck squamous cell carcinoma, demonstrating impressive disease control and response rates, with the combination trial of Alpha DaRT and Keytruda showing particularly noteworthy outcomes. The company is progressing with its U.S. clinical trials and the construction of its new facility in Hudson, NH, as part of its ongoing expansion efforts.